Table 1.
Demographics and neoadjuvant treatment outcomes
| CA 19-9 category | ||||||
|---|---|---|---|---|---|---|
| Characteristic | Total n = 235 | Normal n = 60 | Low n = 78 | Moderate n = 69 | High n = 28 | P-value |
| Age, years median (IQR) | 65 (13) | 66 (14) | 65 (13) | 65 (12) | 62 (14) | 0.83 |
| Gender (Female), n (%) | 115 (49) | 36 (60) | 37 (47) | 32 (47) | 10 (36) | 0.16 |
| BMI, median (IQR) | 25 (7) | 27 (8) | 25 (6) | 26 (8) | 26 (6) | 0.34 |
| Charlson's Comorbidity Index, median (IQR) | 5 (2) | 5 (2) | 5 (2) | 5 (2) | 4 (3) | 0.99 |
| Pre-treatment CA19-9, U/ml median (IQR) | 119 (487) | 14 (23) | 79 (69) | 488 (293) | 2297 (2350) | <0.001 |
| Post-treatment CA19-9, U/ml median (IQR) | 36 (102) | 9 (18) | 34 (44) | 107 (217) | 194 (423) | <0.001 |
| Elevated Post-treatment CA19-9, n (%) | 118 (51) | 4 (7) | 38 (49) | 54 (79) | 22 (81) | <0.001 |
| Clinical Stage, n (%) | <0.001 | |||||
| Resectable | 99 (42) | 28 (47) | 43 (55) | 25 (36) | 3 (11) | |
| Borderline resectable | 136 (58) | 32 (53) | 35 (45) | 44 (64) | 25 (89) | |
| Neoadjuvant therapy, n (%) | ||||||
| Chemotherapy | 42 (18) | 12 (20) | 11 (14) | 12 (17) | 7 (25) | 0.06 |
| Chemoradiation | 86 (37) | 21 (35) | 40 (51) | 20 (29) | 5 (18) | 0.001 |
| Both | 107 (45) | 27 (45) | 27 (35) | 37 (54) | 16 (57) | 0.07 |
| Completed Neoadjuvant and Surgery, n (%) | 168 (71) | 44 (73) | 62 (79) | 46 (67) | 16 (57) | 0.10 |
| Did not undergo pancreatectomy, n (%) | 0.77 | |||||
| Metastases | 50 (21) | 10 (17) | 12 (15) | 18 (26) | 10 (36) | 0.26 |
| Local disease progression | 4 (2) | 2 (3) | 1 (1) | – | 1 (4) | |
| Medical comorbidities | 12 (5) | 3 (5) | 3 (4) | 5 (7) | 1 (4) | |
| Other | 1 (0.4) | 1 (2) | – | – | – | |
IQR, interquartile range; BMI, body mass index; CA, carbohydrate antigen.